BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
Sep 11, 2019 4:30 PM
Oral Presentations:
Title: | Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC) and Nasopharyngeal Carcinoma (NPC) |
Session: | |
Date: | |
Time: | 11:20 – 11:25 |
Location | Auditorium, Level 1 |
Presenter |
Title: | Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: Updated Follow-up Efficacy and Safety Results from a Phase 2 Study |
Session: | Innovative Drug Clinical Data Session 1 |
Date: | |
Time: | 14:30 – 14:40 |
Location | Strait Hall, Level 2 |
Presenter: |
Title: | Tislelizumab in Chinese Patients with Melanoma, Urothelial Carcinoma (UC), and Renal Cell Carcinoma (RCC) |
Session: | Kidney Cancer Session 4 |
Date: | |
Time: | 16:35 – 16:40 |
Location | |
Presenter: |
Title: | Tislelizumab in Chinese Patients with Esophageal Cancer (EC), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC), and Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Tumors |
Session: | Advanced Gastric Cancer Session 3 |
Date: | |
Time: | 11:24 – 11:36 |
Location | Banquet Hall 1, Level 2 |
Presenter: |
Title: | Safety and Efficacy in Patients with Long-Term Exposure (LTE) to Tislelizumab, an Investigational Anti-PD-1 Antibody, in a First-in-Human Phase 1 Study |
Session: | Immuno-Oncology Session 3 |
Date: | |
Time: | 11:54 – 12:00 |
Location | Hall 1G, Level 1 |
Presenter |
Title: | Tislelizumab Plus Chemotherapy as First-Line Treatment for Chinese Patients with |
Session: | |
Date: | |
Time: | 11:38 – 11:44 |
Location | Auditorium, Level 1 |
Presenter: |
Title: | Tislelizumab in Combination with Chemotherapy as Treatment for Chinese Patients with Esophageal Squamous Cell Carcinoma (ESCC) |
Session: | Innovative Drug Clinical Data Session 1 |
Date: | |
Time: | 14:30 – 14:40 |
Location | Banquet Hall 2, Level 2 |
Presenter: | |
Poster Presentations:
Title: | Dose Escalation of Pamiparib in Chinese Patients with High- Grade Non-Mucinous Ovarian Cancer (HGOC) or Advanced Triple-Negative Breast Cancer (TNBC) |
Board #: | P-36 |
Date: | |
Time: | Afternoon |
Location: | Strait Hall Poster Area, Level 2 |
Presenter: |
Title: | Zanubrutinib for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
Board #: | P-45 |
Date: | |
Time: | Morning |
Location: | Strait Hall Poster Area, Level 2 |
Presenter: |
Title: | Zanubrutinib, a Highly Specific BTK Inhibitor in Chinese Patients with Relapsed/Refractory B-cell Malignancies: Follow-up Report of a Phase 1 Trial in |
Board #: | P-46 |
Date: | |
Time: | Morning |
Location: | Strait Hall Poster Area, Level 2 |
Presenter: | Chenmu Du, M.D., |
Title: | The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab |
Board #: | P-60 |
Date: | |
Time: | Morning |
Location: | Strait Hall Poster Area, Level 2 |
Presenter: | Ye Liu, Ph.D., |
About
Investor Contact | Media Contact |
+1 857-302-5189 | +1 857-302-5663 |
ir@beigene.com | media@beigene.com |
__________________________________
1 ABRAXANE®, REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation.